The mRNA trade is whipsawing for a third straight session as the market keeps repricing a single trial readout with no fresh clinical information hitting the tape Friday. Friday’s swing is happening while the broader market barely moves, with the S&P 500 up 0.3% and the NASDAQ 100 up 0.1%. That backdrop shows the volatility is being generated entirely inside the biotech complex, not by any macro shift.
Moderna (NASDAQ:MRNA | MRNA Price Prediction) stock is up 8% to $143.79 Friday morning, extending a violent two-way pattern that has defined the week. Also, BioNTech (NASDAQ:BNTX) shares are up 4% to $114.97, tracking the broader mRNA platform trade. Meanwhile, Merck (NYSE:MRK) stock sits at $149.36 as investors weigh how much of the melanoma readout accrues to the Keytruda franchise.
Moderna rallied 177% on Wednesday after the Phase 3 melanoma win, gave back 18% on Thursday, and was indicated sharply lower Friday before reversing into today’s gain — a repricing exercise as traders reset exposures around a single event.
Third-Session Whipsaw With No New Data
Friday’s session lacks a fresh clinical trigger. The underlying story is unchanged. Moderna and Merck reported that intismeran, their individualized mRNA cancer vaccine, met its primary endpoint in a Phase 3 melanoma trial, showing improvement in recurrence-free and metastasis-free survival when combined with Merck’s Keytruda in patients whose tumors had been surgically removed. It’s the first successful late-stage trial of its kind, and the complete dataset has not been presented publicly and could come at the ESMO conference in Madrid running October 23 to 27.
Sentiment got a boost earlier in the week when Tesla (NASDAQ:TSLA) CEO Elon Musk posted on X that “Despite its obvious misuse during Covid, mRNA has tremendous promise for curing diseases,” adding that “Artificial RNA essentially makes curing diseases a software problem.” Musk was replying to Eric Topol, scientist and founder of the Scripps Research Translational Institute, who framed the melanoma result as building on signs of success in personalized mRNA work against pancreatic, triple-negative breast, and non-small cell lung cancers.
Retail flows have amplified the volatility. One widely shared WallStreetBets post titled “$500k overnight $MRNA” drew 4,914 upvotes and 476 comments, and Reddit sentiment on Moderna currently reads as very bullish across 52 qualified mentions.
Why the Names Are Moving Differently
Moderna owns the readout outright. A credible oncology franchise reshapes the company on top of its infectious-disease base, so Moderna stock carries the full weight of every reassessment. That’s why the stock is up 352% year to date and swinging in double digits between sessions.
BioNTech is running its own individualized mRNA cancer immunotherapy, autogene cevumeran, with Genentech in adjuvant colorectal and pancreatic settings. BioNTech stock trades on broader platform read-across, which is why its move is a fraction of Moderna’s and its year-to-date gain sits at 16%.
Merck co-owns the same pivotal trial, yet Keytruda already anchors a broad approved oncology portfolio. Incremental economics of a single adjuvant melanoma indication are small next to that franchise, though Merck stock is up 44% year to date. The iShares Biotechnology ETF (NASDAQ:IBB) is at $212.28 and up 25% year to date, and Moderna’s presence inside the fund means a single constituent swinging this hard pulls on the ETF’s tape.
What to Watch Now
The positioning tells the story today. Moderna’s full-chain put/call ratio sits at 0.86, with individual expirations swinging from 0.79 near-dated to 8.54 in early October, the kind of chain that produces two-way violence. BioNTech’s chain is 0.28 overall, calmer and call-tilted, which fits its smaller move.
Watch for whether Moderna holds its Friday bid into the close after two prior sessions of full reversals, and whether the ESMO calendar in late October pulls positioning forward, since the complete dataset is the next hard information event for the mRNA trade. Position sizing should reflect that Moderna can still deliver double-digit moves on no news at all (we wrote a free playbook on speculating with just 5% of a portfolio, sizing and exit rules included, here).
Contact [email protected] for any questions or corrections.
Top Gaining Stocks
Top Losing Stocks